3-37007050-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM2PM5PP3_Strong
The NM_000249.4(MLH1):c.440G>T(p.Gly147Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G147E) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.440G>T | p.Gly147Val | missense_variant | 5/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.440G>T | p.Gly147Val | missense_variant | 5/19 | 1 | NM_000249.4 | ENSP00000231790 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary nonpolyposis colon cancer Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Cancer Variant Interpretation Group UK, Institute of Cancer Research, London | Feb 08, 2019 | Data used in classification: UK family 1: three generational family with 4 CRC cases and 1 uterine cancer. Only the proband, CRC age 38, tested for variant. Family of Phillipino origin. (PS4_sup). Absent from GNOMAD, including SE Asians (PM2_sup). Deleterious on AlignGVGD, MAPP, SIFT, Polyphen2, CADD 34 (PP3_sup). MLH1 c.440G>A p.Gly147Glu now classified as 4 by INSIGHT. N.B. Gly to Val considerably more conservative amino acid substitution than Gly to Glu. (PM5_sup). Additional Information (not included in classification): UK family 1: proband: Tumour loss of staining for MLH1/PMS2. BRAF/MLH1 promoter hypermethylation not yet performed. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at